You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Ukraine

Sep 2011

Price: $2,400

About this Report

About this Report

Delivery method: instant download
Report format: PDF doc_pdf.png (download a sample)
Market statistics: Excel workbook doc_excel_table.png (download a sample)

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Ukraine with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Ukraine, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Ukraine for free:

The Consumer Health in Ukraine market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Ukraine?
  • What are the major brands in Ukraine?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Sample Analysis

EXECUTIVE SUMMARY

Sales boosted by economic growth but exaggerated by high inflation

There was strong growth for consumer health during the review period as a whole, with this partly due to good economic growth at the start of the review period. Growth was also boosted by a strong self-medication trend, with this largely linked to inadequacies in the Ukrainian healthcare system. However, growth rates for the review period as a whole were also exaggerated by high inflation in most years, while currency fluctuations also increased the price of imported products towards the end of the review period.

Sales remain muted due to economic downturn

The impact of the economic downturn continued to affect many consumers in 2010, with unemployment and underemployment high, remittances remaining low and inflation high. Consequently, many consumers saw declining disposable income levels, with this constraining their spending on consumer health. Overall constant value sales declined in 2010 over the previous year, while many products saw a sharp decline in current value sales. There was a shift towards home-made remedies in many areas as consumers sought to save money, with this for example hitting sales of diarrhoeal remedies and laxatives hard. There was also less interest in general health-boosters as consumers struggled to meet their food and fuel bills, with vitamins and dietary supplements thus seeing current value sales decline in 2010.

Advertising and widening distribution prove essential in gaining share

The most successful of the leading players at the end of the review period were those who invested in strong advertising or in broadening their distribution reach. Direct selling player Amway was the leading player in 2010 and saw a good growth in share thanks to enlarging its sales force. Second-ranked GlaxoSmithKline meanwhile benefited from offering strong TV advertising support to its brands and also gained share. GlaxoSmithKline notably supported Solpadeine combination analgesics and Coldrex combination cough, cold and allergy (hay fever) remedies with strong advertising.

Chemists/pharmacies loses share to direct selling

Chemists/pharmacies continued to be the dominant distribution channel for consumer health at the end of the review period, with this reflecting restrictive distribution legislation for most products. However, the channel lost value share to direct selling in 2010 over the previous year. Direct selling benefited from Amway’s focus on expansion but also from social and economic trends in Ukraine towards the end of the review period. Rising unemployment and underemployment, alongside growing economic uncertainty, encouraged a growing number of Ukrainians to become direct selling representatives in the hope of supplementing their incomes.

Muted forecast period growth likely due to government controls

Growth for overall consumer health is expected to remain muted during the forecast period. Economic uncertainty is expected to persist into the early years of the forecast period, thus constraining sales. In addition, the government is keen to restrain self-medication and proposed measures such as a ban on advertising for OTC towards the end of the review period. The government also plans to improve consumer access to doctors and thus to Rx medicines during the forecast period. However, economic recovery is expected to result in growth rates slowly increasing during the forecast period as consumer income levels rise.

Table of Contents

Table of Contents

Consumer Health in Ukraine - Industry Overview

EXECUTIVE SUMMARY

Sales boosted by economic growth but exaggerated by high inflation

Sales remain muted due to economic downturn

Advertising and widening distribution prove essential in gaining share

Chemists/pharmacies loses share to direct selling

Muted forecast period growth likely due to government controls

KEY TRENDS AND DEVELOPMENTS

Economic downturn constrains sales growth

Government healthcare reforms pose a challenge to OTC

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2005-2010
  • Table 2 Life Expectancy at Birth 2005-2010

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2005-2010
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2005-2010
  • Table 5 Consumer Health Company Shares by Value 2006-2010
  • Table 6 Consumer Health Brand Shares by Value 2007-2010
  • Table 7 Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
  • Table 8 Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
  • Table 9 Forecast Sales of Consumer Health by Category: Value 2010-2015
  • Table 10 Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

APPENDIX

OTC registration and classification

Vitamins and dietary supplements registration and classification

Self-medication/self-care and preventative medicine

Switches

DEFINITIONS

  • Summary 1 Research Sources

Consumer Health in Ukraine - Company Profiles

Borshagovsky CFF in Consumer Health (Ukraine)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 4 Borshagovsky CFF: Competitive Position 2010

Darnitsa FF ZAT in Consumer Health (Ukraine)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 7 Darnitsa FF ZAT: Competitive Position 2010

Farmak VAT in Consumer Health (Ukraine)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 9 Farmak VAT: Production Statistics 2009

COMPETITIVE POSITIONING

  • Summary 10 Farmak VAT: Competitive Position 2010

Zdorovya FK TOV in Consumer Health (Ukraine)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 12 Zdorovya FK TOV: Production Statistics 2009

COMPETITIVE POSITIONING

  • Summary 13 Zdorovya FK TOV: Competitive Position 2010

Adult Mouth Care in Ukraine - Category Analysis

HEADLINES

TRENDS

  • Growth was maintained in adult mouth care by strong advertising towards the end of the review period. The leading advertiser was Norgine for Givalex, with this brand benefiting from TV advertising highlighting its convenience and efficacy in tackling mouth infections. Many consumers were unwilling to visit dentists towards the end of the review period, due to the high cost of dental treatment and long waiting times. Consequently, many consumers opted to use adult mouth care to treat the pain of infection and toothache, rather than visiting dentists.

SWITCHES

COMPETITIVE LANDSCAPE

  • Norgine was the dominant player in adult mouth care in 2010 and gained a further percentage point in value share over the previous year to account for 54%. This was thanks to strong advertising for the company’s Givalex brand. This advertising emphasised the convenience of the brand’s spray and mouthwash formats and its efficacy in treating mouth and throat infections.

PROSPECTS

  • Sales will continue to benefit from a growing focus on oral health during the forecast period. Many consumers will regard the use of adult mouth care as a good means of improving dental health and thus minimising the need for dental visits. However, adult mouth care will face strong competition from mouthwashes/dental rinses within beauty and personal care. Many brands in mouthwashes/dental rinses make strong oral health claims, with these products being cheaper and more strongly advertised in comparison to adult mouth care.

CATEGORY DATA

  • Table 11 Sales of Adult Mouth Care: Value 2005-2010
  • Table 12 Sales of Adult Mouth Care: % Value Growth 2005-2010
  • Table 13 Adult Mouth Care Company Shares by Value 2006-2010
  • Table 14 Adult Mouth Care Brand Shares by Value 2007-2010
  • Table 15 Forecast Sales of Adult Mouth Care: Value 2010-2015
  • Table 16 Forecast Sales of Adult Mouth Care: % Value Growth 2010-2015

Analgesics in Ukraine - Category Analysis

HEADLINES

TRENDS

  • Under-the-counter sales of Rx analgesics continued to be strong at the end of the review period, with most chemists/pharmacies offering these products to customers without a prescription. However, the government did seek to clamp down on such sales and increased their use of spot checks and fines. In response, many chemists/pharmacies began to encourage consumers to opt for OTC products where possible, with this trend greatly boosting sales of OTC analgesics.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline was a clear leader in analgesics in 2010 and also saw the strongest growth in value share, with a rise of three percentage points from 2009 to 20% share. The company offers Panadol and Panadol Extra in acetaminophen and leading combination products brand Solpadeine, along with dominating child-specific acetaminophen where its Panadol Baby brand accounted for 70% value share in 2010. The company’s share growth was mainly due to the strong performance of Solpadeine in 2010, with this brand continuing to benefit from strong marketing. As a result of the brand’s strong advertising towards the end of the review period, many consumers began to regard it as more effective than other combination products.

PROSPECTS

  • Analgesics is expected to continue to benefit from stricter controls on sales of Rx medicines during the forecast period. The Ukrainian government appears committed to reforming the country’s healthcare system. While offering easier access to doctors and thus to prescriptions, the government will also seek to prevent the misuse and illegal sale of Rx analgesics under-the-counter. Consequently, consumers will increasingly be forced to purchase OTC analgesics if they do not have a prescription.

CATEGORY DATA

  • Table 17 Sales of Analgesics by Category: Value 2005-2010
  • Table 18 Sales of Analgesics by Category: % Value Growth 2005-2010
  • Table 19 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2005-2010
  • Table 20 Analgesics Company Shares by Value 2006-2010
  • Table 21 Analgesics Brand Shares by Value 2007-2010
  • Table 22 Forecast Sales of Analgesics by Category: Value 2010-2015
  • Table 23 Forecast Sales of Analgesics by Category: % Value Growth 2010-2015

Calming and Sleeping in Ukraine - Category Analysis

HEADLINES

TRENDS

  • The economic downturn and rising consumer stress did not prove beneficial for calming and sleeping products at the end of the review period. Instead of buying OTC calming and sleeping products more frequently, many consumers switched to home-made herbal remedies in order to save money. There is a strong tradition of herbal medicine in Ukraine, with many regarding home-made remedies as effective, cheap healthier in comparison to packaged products. Consequently, sedative teas prepared from herbs such as valerian and motherwort proved increasingly popular.

SWITCHES

COMPETITIVE LANDSCAPE

  • UPSA, Lek and Effect were the leading players in calming and sleeping products in 2010, accounting for 14%, 12% and 10% value share respectively. UPSA derives its share from Donormyl and Effect from Phytosedum, while Lek offers the Persen and Persen Forte brands. These brands benefit from TV advertising support and the use of booklets and posters in chemists/pharmacies.

PROSPECTS

  • Calming and sleeping products is expected to face even stronger competition from Rx products during the forecast period. The government plans to impose stricter controls on sales of Rx products without a prescription. However, this is not expected to result in a shift towards OTC sales, as the government also plans to improve consumers’ access to doctors and to introduce healthcare insurance. Consequently, consumers are expected to increasingly opt for Rx medicines via prescription, particularly if these products can be reimbursed via their health insurance.

CATEGORY DATA

  • Table 24 Sales of Calming and Sleeping: Value 2005-2010
  • Table 25 Sales of Calming and Sleeping: % Value Growth 2005-2010
  • Table 26 Calming and Sleeping Company Shares by Value 2006-2010
  • Table 27 Calming and Sleeping Brand Shares by Value 2007-2010
  • Table 28 Forecast Sales of Calming and Sleeping: Value 2010-2015
  • Table 29 Forecast Sales of Calming and Sleeping: % Value Growth 2010-2015

Cough, Cold and Allergy (Hay Fever) Remedies in Ukraine - Category Analysis

HEADLINES

TRENDS

  • Ukraine was gripped by swine flu hysteria in autumn 2009, with this continuing into 2010. There was for example a ban on public gatherings throughout November 2009 and schools were closed, while chemists/pharmacies ran out of supplies of protective masks. However, this did not result in a dramatic upsurge in sales of OTC cough, cold and allergy (hay fever) remedies or even in vaccinations. Instead, the Prime Minister at the time, Yulia Tymoshenko announced in November 2009 that she was not vaccinated and that she would rely upon traditional remedies such as lemon, onion and garlic. There were also calls to introduce a ban on advertising for OTC cough, cold and allergy (hay fever) remedies in order to deter self-medication.

SWITCHES

COMPETITIVE LANDSCAPE

  • Farmak was the leading player in 2010 and gained a further third of a percentage point over the previous year to account for 12% share. Farmak mainly benefited from the strong performance of Amizon in combination products towards the end of the review period, with this being positioned as effective against new kinds of flu virus. Given widespread concerns over the swine flu epidemic towards the end of the review period, this product saw strong popularity. Amizon also benefited from TV advertising and from its lower price in comparison to imported products.

PROSPECTS

  • Sales growth is expected to be muted for cough, cold and allergy (hay fever) remedies during the forecast period, with a CAGR of less than 1%. This will be due to a number of factors. The strong popularity of traditional remedies is expected to constrain sales, with many consumers regarding these as more effective than packaged cough, cold and allergy (hay fever) remedies. In addition, most product areas are largely mature. Consequently, growth is expected to drop from the 3% constant value CAGR seen during the review period.

CATEGORY DATA

  • Table 30 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 32 Sales of Decongestants by Category: Value 2005-2010
  • Table 33 Sales of Decongestants by Category: % Value Growth 2005-2010
  • Table 34 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 35 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 36 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2006-2010
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2007-2010
  • Table 38 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Digestive Remedies in Ukraine - Category Analysis

HEADLINES

TRENDS

  • Sales of digestive remedies suffered in 2010 as consumers switched to cheaper home-made remedies. Many consumers faced economic uncertainty towards the end of the review period, with those suffering from low-level symptoms thus cutting back on purchases. Home-made remedies based on herbs and/or dried fruit also proved popular as consumers sought to save money. This trend particularly impacted diarrhoeal remedies, antiflatulents, laxatives and motion sickness remedies, with the latter product area also being hit by a decline in holiday-taking following the economic downturn. Consequently, diarrhoeal remedies and laxatives saw 8% and 10% current value decline in 2010 over the previous year, while antiflatulents declined by 11% and motion sickness remedies by 12%.

SWITCHES

COMPETITIVE LANDSCAPE

  • Chinoin Pharmaceutical & Chemical Works was the leading player in digestive remedies in 2010, accounting for 16% value share. This is entirely due to the company’s well-advertised No-spa brand, which dominated IBS treatments in 2010 with 89% value share. No-spa was largely responsible for the strong growth seen in IBS treatments during the review period, with the brand’s TV advertising doing much to educate consumers about this condition. The brand is also positioned as soothing the pain of menstrual cramps and thus gained a strong appeal amongst female consumers during the review period. Strong advertising support enabled the brand to gain an additional two percentage points in value share in 2010 over the previous year.

PROSPECTS

  • Digestive remedies is expected to benefit from the Ukraine’s economic recovery during the forecast period. Not only will rising disposable income levels enable consumers to spend more on digestive remedies but will also result in consumers eating richer foods, socialising more and thus drinking more alcohol. This trend will thus boost the incidence of digestive disorders and boost sales.

CATEGORY DATA

  • Table 40 Sales of Digestive Remedies by Category: Value 2005-2010
  • Table 41 Sales of Digestive Remedies by Category: % Value Growth 2005-2010
  • Table 42 Digestive Remedies Company Shares by Value 2006-2010
  • Table 43 Digestive Remedies Brand Shares by Value 2007-2010
  • Table 44 Forecast Sales of Digestive Remedies by Category: Value 2010-2015
  • Table 45 Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015

Ear Care in Ukraine - Category Analysis

HEADLINES

TRENDS

  • There was dynamic growth in ear care in 2009, with this linked to the rising price of Rx medicines. Due to currency fluctuations, the price of Rx ear care increased while consumers’ disposable income levels simultaneously declined as a result of the economic downturn. Consequently, many consumers switched to OTC ear care in 2009, with this fuelling a striking 46% current value growth. This left little room for further growth in 2010, with sales thus stabilising and seeing only marginal current value growth. 2010 thus saw considerably lower current value growth in comparison to a review period CAGR of 17%.

SWITCHES

COMPETITIVE LANDSCAPE

  • Aventis was the clear leader in ear care in 2010 and also saw the strongest growth in value share in the year. The company gained an impressive seven percentage points for its Sofradex brand from 2009 to account for 32% value share in 2010. This was chiefly due to the brand gaining share from its main competitor, Biocodex’s Otipax.

PROSPECTS

  • Ear care is expected to be hindered by improved consumer access to doctors, as a result of government improvements to the country’s healthcare system. Consumers generally prefer to seek medical advice for ear problems and access to doctors is expected to improve during the forecast period, with more doctors operating, shorter waiting times and the introduction of health insurance. This is expected to result in a shift from OTC to Rx sales within ear care.

CATEGORY DATA

  • Table 46 Sales of Ear Care: Value 2005-2010
  • Table 47 Sales of Ear Care: % Value Growth 2005-2010
  • Table 48 Ear Care Company Shares by Value 2006-2010
  • Table 49 Ear Care Brand Shares by Value 2007-2010
  • Table 50 Forecast Sales of Ear Care: Value 2010-2015
  • Table 51 Forecast Sales of Ear Care: % Value Growth 2010-2015

Emergency Contraception in Ukraine - Category Analysis

HEADLINES

TRENDS

  • Emergency contraception suffered from two main factors at the end of the review period. Firstly, the high price of these products deterred many consumers in 2009 and 2010, as the economic downturn eroded many consumers’ disposable income levels. Many consumers were simply unable to afford emergency contraception, particularly as unregulated prices resulted in a wide variance in price across chemists/pharmacies.

COMPETITIVE LANDSCAPE

  • Emergency contraception also suffered from a lack of competition at the end of the review period, with Richter Gedeon being the only player. This company launched Postinor in 2007 and Escapelle in 2008. Postinor continued to dominate sales in 2010 due to its earlier entry, with the brand accounting for 82% value share in 2010. Escapelle meanwhile accounted for 18% value share.

PROSPECTS

  • Emergency contraception will continue to be constrained by ongoing consumer price-sensitivity during the forecast period. High levels of unemployment and high inflation will result in ongoing consumer price-sensitivity, with many unable to afford emergency contraception as a result. Consequently, sales are expected to continue to decline for the first two years of the forecast period and to achieve only slow growth in the second half of the forecast period. Overall, constant value sales are expected to decline by 1% during the forecast period.

CATEGORY DATA

  • Table 52 Sales of Emergency Contraception: Value 2007-2010
  • Table 53 Sales of Emergency Contraception: % Value Growth 2007-2010
  • Table 54 Emergency Contraception Company Shares by Value 2006-2010
  • Table 55 Emergency Contraception Brand Shares by Value 2007-2010
  • Table 56 Forecast Sales of Emergency Contraception: Value 2010-2015
  • Table 57 Forecast Sales of Emergency Contraception: % Value Growth 2010-2015

Eye Care in Ukraine - Category Analysis

HEADLINES

TRENDS

  • Declining disposable income levels at the end of the review period resulted in many consumers switching from eye care to home-made remedies in order to save money. Camomile tea is for example a popular remedy for tired and sore eyes in the country. Sales also suffered from rising unemployment levels, with many office workers facing unemployment or reduced working hours. For these consumers, there was thus no longer a need for eye care to soothe eyes during long working hours.

SWITCHES

COMPETITIVE LANDSCAPE

  • Pfizer was the clear leader in eye care at the end of the review period, accounting for 29% value share. This was thanks to the strength of its Visine brand in standard eye care, where it led with 30% share. Visine benefits from strong consumer recognition, due to a high-profile TV advertising presence throughout the review period.

PROSPECTS

  • Sales growth is expected to be muted by two main factors during the forecast period. Firstly, while the country is expected to see economic recovery during the forecast period many consumers will continue to struggle at the start of the forecast period. This is expected to result in many consumers continuing to use home-made remedies rather than purchasing eye care.

CATEGORY DATA

  • Table 58 Sales of Eye Care by Category: Value 2005-2010
  • Table 59 Sales of Eye Care by Category: % Value Growth 2005-2010
  • Table 60 Standard Eye Care by Type: % Value Breakdown 2007-2010
  • Table 61 Eye Care Company Shares by Value 2006-2010
  • Table 62 Eye Care Brand Shares by Value 2007-2010
  • Table 63 Forecast Sales of Eye Care by Category: Value 2010-2015
  • Table 64 Forecast Sales of Eye Care by Category: % Value Growth 2010-2015

Herbal/Traditional Products in Ukraine - Category Analysis

HEADLINES

TRENDS

  • There was growing awareness of and interest in herbal/traditional OTC towards the end of the review period. This was partly due to the widening distribution of products such as herbal/traditional topical analgesics/anaesthetic and medicated skin care. In addition, this trend was encouraged by consumer concerns about the potentially hazardous side effects associated with standard OTC products and the misuse of Rx medicines. Many consumers believe that herbal/traditional products are free from side effects and are thus considerably safer for self-medication. Many herbal/traditional OTC products thus saw a strong performance, with herbal/traditional analgesics notably seeing 44% current value growth in 2010. Herbal/traditional medicated skin care saw 16% growth in the year while herbal/traditional cough, cold and allergy (hay fever) remedies saw 14% growth.

COMPETITIVE LANDSCAPE

  • Herbal/traditional products is highly fragmented, with the leading players focusing on specific product areas rather than offering a wide range of herbal/traditional products. Leading player Aim accounted for just 4% value share, followed by Lek and Pharma Wernigerode with 2% value share each in 2010. Aim owes its strength to a strong 41% lead in herbal/traditional medicinal teas, where the company continued to grow sales thanks to expanding distribution. Lek meanwhile offers Persen, Persen Forte and Sanason in herbal/traditional calming and sleeping products, where the company accounted for 8% value share in 2010, and accounted for 5% share in herbal/traditional dietary supplements with the Immunal brand. Pharma Wernigerode meanwhile dominates herbal/traditional medicated skin care with its Eskuzan haemorrhoid treatments brand.

PROSPECTS

  • A growing focus on natural nutrition and Ukraine’s tradition of herbal remedies is expected to boost sales during the forecast period. Consumers are becoming more sophisticated in their understanding of consumer health and are increasingly questioning the side effects associated with standard products. Simultaneously, there was growing interest in the gentler remedies offered by herbs.

CATEGORY DATA

  • Table 65 Sales of Herbal/Traditional Products: Value 2005-2010
  • Table 66 Sales of Herbal/Traditional Products: % Value Growth 2005-2010
  • Table 67 Herbal/Traditional Products Company Shares 2006-2010
  • Table 68 Herbal/Traditional Products Brand Shares 2007-2010
  • Table 69 Forecast Sales of Herbal/Traditional Products: Value 2010-2015
  • Table 70 Forecast Sales of Herbal/Traditional Products: % Value Growth 2010-2015

Medicated Skin Care in Ukraine - Category Analysis

HEADLINES

TRENDS

  • The economic downturn dampened sales of medicated skin care in the last two years of the review period, with consumers cutting back on their spending in many product areas in order to save money. Many consumers switched from products such as nappy (diaper) rash treatments and antipruritics to simple moisturisers and from topical germicidals/antiseptics to cheaper alternatives such as alcohol in order to save money.

SWITCHES

COMPETITIVE LANDSCAPE

  • STADA Arzneimittel was the leading player in medicated skin care in 2010 with almost 10% value share and also saw the strongest gain in share of three percentage points. The company benefited from offering strong advertising support for its Proctosan haemorrhoid treatments, Psilo-Balsam topical allergy remedies/antihistamines and Aciclovir cold sore treatments. All three brands also benefited from widening distribution and thus saw strong growth in 2010 over the previous year.

PROSPECTS

  • Cosmetic skin care is expected to pose growing competition to medicated skin care during the forecast period. Cosmetic products typically benefit from stronger advertising support, including celebrity endorsements, and wider distribution. Consequently, many consumers are likely to be attracted by these products during the forecast period, with this constraining sales growth in acne treatments, medicated shampoos and hair loss treatments.

CATEGORY DATA

  • Table 71 Sales of Medicated Skin Care by Category: Value 2005-2010
  • Table 72 Sales of Medicated Skin Care by Category: % Value Growth 2005-2010
  • Table 73 Acne Treatments by Format: % Value Breakdown 2005-2010
  • Table 74 Medicated Skin Care Company Shares by Value 2006-2010
  • Table 75 Medicated Skin Care Brand Shares by Value 2007-2010
  • Table 76 Acne Treatments Brand Shares by Value 2007-2010
  • Table 77 Hair Loss Treatments Brand Shares by Value 2007-2010
  • Table 78 Forecast Sales of Medicated Skin Care by Category: Value 2010-2015
  • Table 79 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2010-2015

NRT Smoking Cessation Aids in Ukraine - Category Analysis

HEADLINES

TRENDS

  • Ukraine has fairly strong anti-smoking legislation. Health warnings must occupy no less than 30% of the front and back of cigarette packs. The legal smoking age is 18-years-old and smoking is banned in many enclosed public places while the sale and advertising of tobacco products is also restricted.

SWITCHES

COMPETITIVE LANDSCAPE

  • NRT smoking cessation aids suffered from a lack of choice at the end of the review period. The sole product on offer in the country was Pharmacia’s Nicorette NRT gum in mint and original/classic flavours. There was thus little choice or competition within NRT smoking cessation aids, with Pharmacia having little incentive to compete on price or to challenge competitors through effective marketing or new product development.

PROSPECTS

  • The government plans to use legislation to further reduce the incidence of smoking during the forecast period. In January 2011, the minimum excise on filter cigarettes rose by UAH0.2 per box to an average 44% share of pack price. Further increases are likely, with EU directives stating that excise should account for no less than 57% of pack price. The government is also expected to impose a full public smoking ban and to ban tobacco advertising, while also clamping down on illegal tobacco sales.

CATEGORY INDICATORS

  • Table 80 Number of Smokers by Gender 2005-2010

CATEGORY DATA

  • Table 81 Sales of NRT Smoking Cessation Aids by Category: Value 2005-2010
  • Table 82 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2005-2010
  • Table 83 NRT Gum Flavours: % Value Breakdown 2006-2010
  • Table 84 NRT Smoking Cessation Aids Company Shares by Value 2006-2010
  • Table 85 NRT Smoking Cessation Aids Brand Shares by Value 2007-2010
  • Table 86 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2010-2015
  • Table 87 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2010-2015

Sports Nutrition in Ukraine - Category Analysis

HEADLINES

TRENDS

  • Sports nutrition gained a significant presence for the first time in 2009, with this due to Amway launching Nutrilite Protein Powder in Ukraine. This attracted many athletes and body builders by offering an unflavoured, neutral-tasting and low-fat powder that can easily be added to food and drinks. Growth was also driven by Amway expanding its sales force in the last two years of the review period and thus boosting awareness of sports nutrition.

COMPETITIVE LANDSCAPE

  • Sports nutrition only emerged in 2009 and there was only one significant product at the end of the review period: Amway’s Nutrilite Protein Powder. This was sold online and via the company’s expanding direct selling force and priced at around UAH320 for 450g in November 2010. This product is thus unaffordable for many sports people, with many instead opting to eat protein-rich diets.

PROSPECTS

  • Amway is likely to continue to drive growth in sports nutrition during the forecast period. The company is expected to see a further increase in its sales force during the forecast period, attracting many unemployed or underemployed workers. This sales force will meanwhile continue to explain the nutritional benefits of Nutrilite Protein Powder and will also be able to answer consumers’ questions. Amway is thus likely to support stronger consumer awareness of sports nutrition, which is likely to gain a more mainstream positioning as a result.

CATEGORY DATA

  • Table 88 Sales of Sports Nutrition: Value 2009-2010
  • Table 89 Sales of Sports Nutrition: % Value Growth 2009-2010
  • Table 90 Sports Nutrition By Format: % Value Breakdown 2007-2010
  • Table 91 Sports Nutrition Company Shares 2006-2010
  • Table 92 Sports Nutrition Brand Shares 2007-2010
  • Table 93 Forecast Sales of Sports Nutrition: Value 2010-2015
  • Table 94 Forecast Sales of Sports Nutrition: % Value Growth 2010-2015

Vitamins and Dietary Supplements in Ukraine - Category Analysis

HEADLINES

TRENDS

  • In the first half of the review period, vitamins and dietary supplements saw striking growth. Consumers became increasingly focused on nutrition and health and interested in the role that vitamins and dietary supplements plays, with this encouraged by growing media coverage. This supported an impressive 14% current value CAGR in vitamins and dietary supplements for the review period as a whole, although much of this strong growth was also due to high levels of inflation.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Amway was the clear leader in vitamins and dietary supplements at the end of the review period with 19% value share. By 2010, Amway was the leading player in child-specific vitamins and dietary supplements, combination dietary supplements, mineral supplements, multivitamins and single vitamins. This leading position is thanks to the company’s wide range, reputation for quality and strong sales techniques.

PROSPECTS

  • Vitamins and dietary supplements is expected to greatly benefit from two major factors during the forecast period. Firstly, there is expected to be a growing interest in health and nutrition, with consumers increasingly focusing on optimum health rather than simply treating the symptoms of disease. This trend will be encouraged by strong marketing by players such as Amway and is expected to particularly benefit products based on natural ingredients such as ginseng and berry.

CATEGORY DATA

  • Summary 14 Dietary Supplements: Brand Ranking by Positioning 2010
  • Table 95 Sales of Vitamins and Dietary Supplements by Category: Value 2005-2010
  • Table 96 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2005-2010
  • Table 97 Dietary Supplements by Positioning 2005-2010
  • Table 98 Vitamins and Dietary Supplements Company Shares by Value 2006-2010
  • Table 99 Vitamins and Dietary Supplements Brand Shares by Value 2007-2010
  • Table 100 Vitamins Brand Shares by Value 2007-2010
  • Table 101 Dietary Supplements Brand Shares by Value 2007-2010
  • Table 102 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2010-2015
  • Table 103 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2010-2015

Weight Management in Ukraine - Category Analysis

HEADLINES

TRENDS

  • OTC obesity emerged in 2006 for the first time with the launch of Hoffman La Roche’s Xenical. This brand initially saw a surging interest, notably seeing 40% current value growth in 2007 over the previous year due to its novelty and promise of an easy means of losing weight. Growth was also initially driven by strong TV advertising support.

COMPETITIVE LANDSCAPE

  • Amway largely defined the performance of weight management throughout the review period. At the start of the review period, the company was the only player, with its Nurilite Positrim accounting for all sales. The company saw its share plummet following the introduction of Hoffman La Roche’s Xenical in 2006, dropping to just 59% value share in 2007.

PROSPECTS

  • Amway is expected to continue to drive growth in weight loss supplements and thus in overall weight management during the forecast period. The company will continue to expand its sales force at the start of the forecast period. This will be facilitated by the interest of numerous part-time workers and those struggling to make ends meet, with the company also likely to attract many of the large number of unemployed workers.

CATEGORY DATA

  • Table 104 Sales of Weight Management: Value 2005-2010
  • Table 105 Sales of Weight Management: % Value Growth 2005-2010
  • Table 106 Weight Management Company Shares 2006-2010
  • Table 107 Weight Management Brand Shares 2007-2010
  • Table 108 Forecast Sales of Weight Management: Value 2010-2015
  • Table 109 Forecast Sales of Weight Management: % Value Growth 2010-2015

Wound Care in Ukraine - Category Analysis

HEADLINES

TRENDS

  • The impact of the economic downturn could clearly be seen in 2009. The year saw strong growth for gauze, tape and “other” wound care at 28% in current value terms and just 1% growth for sticking plasters/adhesive bandages. Consumers increasingly opted for generic Bint or bandages, with these offering a low pack price and a large number of applications. In 2010, many consumers were thus still using stocks of bandages purchased in 2009.

COMPETITIVE LANDSCAPE

  • Veropharm was the clear leader in wound care in 2010, accounting for almost 28% value share. This company’s Veropharm Plaster brand is viewed as offering superior adhesiveness and breathability in comparison to domestic plasters, along with offering invisibility, antiseptic benefits and water resistance. Simultaneously, however, the company’s sticking plasters/adhesive bandages are priced at a lower level in comparison to other imported brands. The company gained a further percentage point in value share in 2010 over the previous year, benefiting from offering an affordable price and high quality.

PROSPECTS

  • Wound care may well benefit from widening distribution during the forecast period, improving consumers’ access to these products. Wound care gained a growing presence in parapharmacies/drugstores towards the end of the review period. This presence is expected to grow further during the forecast period, with the government also likely to liberalise distribution. If wound care begins to be sold via supermarkets/hypermarkets, sales are likely to see stronger growth during the forecast period and constant value unit prices could well be pushed down thanks to growing price competition.

CATEGORY DATA

  • Table 110 Sales of Wound Care by Category: Value 2005-2010
  • Table 111 Sales of Wound Care by Category: % Value Growth 2005-2010
  • Table 112 Wound Care Company Shares by Value 2006-2010
  • Table 113 Wound Care Brand Shares by Value 2007-2010
  • Table 114 Forecast Sales of Wound Care by Category: Value 2010-2015
  • Table 115 Forecast Sales of Wound Care by Category: % Value Growth 2010-2015

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Acne Treatments
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Child-Specific Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
    • Vitamins and Dietary Supplements
      • Child-Specific Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Berry
            • Isoflavones
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
            • Sea Products
            • Yeast
      • Tonics and Bottled Nutritive Drinks
      • Vitamins
        • Multivitamins
        • Single Vitamins
          • Vitamin A
          • Vitamin B
          • Vitamin C
          • Vitamin D
          • Vitamin E
          • Other Single Vitamins
    • Weight Management
      • Meal Replacement Slimming
      • OTC Obesity
      • Slimming Teas
      • Weight Loss Supplements
      • Other Slimming Products
    • Herbal/Traditional Products
      • Herbal/Traditional Analgesics
      • Herbal/Traditional Calming and Sleeping Products
      • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
      • Herbal/Traditional Digestive Remedies
      • Herbal/Traditional Medicated Skin Care
      • Herbal/Traditional Medicinal Teas
      • Herbal/Traditional Smoking Cessation Aids
      • Herbal/Traditional Child-Specific Dietary Supplements
      • Herbal/Traditional Dietary Supplements
      • Herbal/Traditional Tonics and Bottled Nutritive Drinks
    • Allergy Care
      • Allergy Eye Care
      • Antihistamines/Allergy Remedies (Systemic)
      • Child-Specific Allergy Remedies
      • Topical Allergy Remedies/Antihistamines
    • Child-Specific Consumer Health
      • Child-Specific Analgesics
        • Child-Specific Acetaminophen
        • Child-Specific Aspirin
        • Child-Specific Combination Products - Analgesics
        • Child-Specific Diclofenac
        • Child-Specific Dipyrone
        • Child-Specific Ibuprofen
        • Child-Specific Ketoprofen
        • Child-Specific Naproxen
      • Child-Specific Cough, Cold and Allergy Remedies
        • Child-Specific Allergy Remedies
        • Child-Specific Cough/Cold Remedies
      • Child-Specific Digestive Remedies
        • Child-Specific Diarrhoeal Remedies
        • Child-Specific Indigestion and Heartburn Remedies
        • Child-Specific Laxatives
        • Child-Specific Motion Sickness Remedies
      • Child-Specific Medicated Skin Care
      • Nappy (Diaper) Rash Treatments
      • Child-Specific Vitamins and Dietary Supplements

Statistics Included

Statistics Included

For each category and subcategory you will receive the following data in Excel format:

From Passport

  • Market sizes
  • Company shares
  • Brand shares
  • Distribution
  • Analysis by format
  • Analysis by positioning
  • Analysis by type
  • Herbal/traditional vs standard
  • Pricing
  • Smoking population - number of adult smokers
  • Smoking prevalence - % of adult population

Market size details:

  • Retail volume
  • Retail volume % growth
  • Retail volume per capita
  • Retail value retail selling price % growth
  • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price real (constant 2008) prices % growth
  • Retail value retail selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price % growth
  • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price real (constant 2008) prices % growth
  • Retail value manufacturer selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price nominal (current) prices % growth
  • Retail value retail selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price nominal (current) prices % growth
  • Retail value manufacturer selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY

Methodology

Methodology

Global insight and local knowledge

With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

Industry specialists

Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

Country and regional analysts

Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

In-country research network

To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

Research Methodology

Our research methods

Each Euromonitor International industry report is based on a core set of research techniques:

Desk research

With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

  • National statistics offices governmental and official sources
  • National and international trade press
  • National and international trade associations
  • Industry study groups and other semi-official sources
  • Company financials and annual reports
  • Broker reports
  • Online databases
  • The financial, business and mainstream press

Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

Store checks

Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

  • Place: We track products in all relevant channels, selective and mass, store and non-store
  • Product: What are innovations in products, pack sizes and formats?
  • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
  • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

Trade survey

Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

Trade surveys allow us to:

  • Fill gaps in available published data per company
  • Generate a consensus view of the size, structure and strategic direction of the category
  • Access year-in-progress data where published sources are out of date
  • Evaluate the experts’ views on current trends and market developments

In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

Company analysis

At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

Forecasts

Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

Data validation

All data is subjected to an exhaustive review process, at country, regional and global levels.

The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

Market analysis

Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

my pages

Want to find out more about this report?

RELATED

Country Report

Consumer Lifestyle

Future Demographic

Country Report